ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / KEQU / options
SERA (30) BNR (20) XGN (36) TLSI (31) ⌘ Pro Terminal β†’

Kewaunee Scientific Corporation (KEQU) Options Positioning, Max Pain & Unusual Sweeps

$33.44 -0.21% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $33.36

Kewaunee Scientific Corporation (KEQU) carries a Roarable Rating of C+ (Hold) with 69/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

πŸ“Š Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY) β†’
ROARABLE C+ β€’ HOLD / WATCH Cap $97.0M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on KEQU Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.44 (-0.21% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #97 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does KEQU compare to SERA and BNR in the Health Care sector?
β–Ό

Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, SERA (Sera Prognostics Inc. (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M) and BNR (Burning Rock Biotech Limited) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $116.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for KEQU?
β–Ό

Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $33.36 (-0.23%)🧬 Cannibal Buyback (-2.92% YoY Shares)βš™οΈ Cash Engine: 17/20 (A-) β€’ 6.6% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 69/100 (C+) historically posted market-perform odds over rolling 90-day windows (+2.0% avg 90D alpha vs SPY β€’ 57.3% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERHOLD / WATCH β€’ C+
025507510069
2-of-3 JEV AI Jury Bullish
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ Β· Rk B-
Cash (17)Whales (6)SEC (16)Macro (12)CEO (18)
Each axis scored 0–20
12M PRICE TARGET CONE+5% Base Target
$46 Bull$35 Base$27 Bear
πŸ“¬ FREE KEQU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for KEQU)Realized 20D OHLCV Swing Band: Β±5%
Deterministic 5-Pillar Attribution (69/100 Composite)
πŸ” WHY KEQU SCORES 69/100 (C+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Insider Conviction & Share Dilution+18/20 pts (26% of score)

SEC Form 4 / 13F Thermometer: 86% Net Buy β€’ Cannibal Buyback (-2.92% YoY Shares)

β–² #2 Bullish Driver: Cash Engine Quality+17/20 pts (25% of score)

SEC XBRL FY 2025 (10-K): 6.6% FCF Margin ($18.6M FCF) & 28.5% Gross Margin

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning6/20 pts (-14 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-14 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
61
Grade C$32.40-0.9% Next Q
Q2 (-2Q)
64
Grade C+$32.10+1% Next Q
Q3 (-1Q)
66
Grade B-$32.42+3.1% Next Q
Current
69
Grade C+$33.44+2% Hist 90D Ξ±
Trajectory: C (61) β†’ C+ (69)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

βš”οΈ Adversarial Opposing Case: Why the KEQU Bull Thesis Could Fail

Gideon Ashmere Forensic Desk β†’

Even with a 69/100 (C+) score, KEQU faces multiple-compression risk if 10.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.92% YoY Shares) β€” any gross margin slip below 26.0% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($34.54) or 200D SMA ($36.80) invalidates the momentum regime and cuts Target Base ($35.10) toward Bear Floor ($27.38).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $KEQUβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œKEQU Beats Next Quarter EPS Consensus (Jan 28, 2027) & Holds Above 200D SMA”
YES 69%NO 31%Trade / Inspect Odds β†’
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (KEQU)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for KEQU.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher + Options & Swing Structure Desk

Whale Flow & Momentum Playbook: Evaluating KEQU & AI Leaders Without Chasing Tops

  • βœ“Institutional whale strikes & implied earnings move audit on KEQU
  • βœ“How disciplined traders manage risk using pre-published trigger & invalidation levels
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on tracked leaders
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
KEQU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.35%β–Ό DESCENDING CHANNEL
2026-11-02O $34.72H $34.72L $33.44C $33.44VOL 1.9K
RES: $37.31SUP: $31.13SMA50: $34.54SMA200: $36.80
$43.38$40.30$37.21$34.13$31.04RES $37.31SUP $31.13$33.442026-05-042026-06-172026-08-042026-09-172026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KEQU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ KEQU Butterfly Map β†’ + Track KEQU β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
-1.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KEQU today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for KEQU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for KEQU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KEQU)

Health Care Rank #97 of 1016 βš”οΈ SERA vs KEQU Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (KEQU vs. SERA, BNR, XGN, TLSI)

Industry: Medical Specialities (41 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kewaunee Scientific Corporation (KEQU) ranks #97 by composite RQD confidence (69/100, grade C+) and #664 by equity capitalization ($97.0M). Within this direct 5-issuer industry benchmark cohort, KEQU leads on earnings valuation at 10.1x trailing P/E, while KEQU leads on capital efficiency and profitability with 16.7% ROIC and 28.5% gross margin. KEQU currently leads its immediate peer cohort in composite quantitative strength at 69/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
KEQU ACTIVE
Kewaunee Scientific Corporation
C+ 69/100 10.1x 28.5% 16.7% -0.21% $97.0M Benchmark Subject
SERA
Sera Prognostics Inc. (Class A)
E 30/100 β€” -30.0% -35.0% -0.97% $81.3M /sera-vs-kequ β†’
BNR
Burning Rock Biotech Limited
E 20/100 β€” 74.7% -35.0% -1.36% $116.5M /bnr-vs-kequ β†’
XGN
Exagen Inc.
D- 36/100 β€” 58.3% -35.0% -1.26% $210.8M /xgn-vs-kequ β†’
TLSI
TriSalus Life Sciences Inc.
E 31/100 β€” 84.6% -35.0% -4.14% $237.7M /tlsi-vs-kequ β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2026-04-30 β€’ CIK 0000055529

In its most recent audited fiscal period (FY2025, filed 2026-04-30), Kewaunee Scientific Corporation (KEQU) reported GAAP revenue of $282.0M (+17.3% vs. FY2024 revenue of $240.5M , and +38.4% cumulative change since FY2023) , GAAP net income of $9.6M, operating cash flow of $18.6M, and free cash flow of $18.6M (+26.0% YoY). On the balance sheet, KEQU closed FY2025 with $176.0M in total assets against $16.3M in total debt (Altman Z-Score: 3.37, Piotroski F-Score: 8/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-04-30 $282.0M $9.6M $18.6M $18.6M $176.0M $16.3M
FY2024 (FY) 2025-04-30 $240.5M $11.4M $14.8M $14.8M $189.1M $35.0M
FY2023 (FY) 2024-04-30 $203.8M $18.8M $19.6M $19.6M β€” β€”

3. KEQU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KEQU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, Kewaunee Scientific Corporation (NASDAQ: KEQU) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 69/100 at a spot price of $33.44 (-0.21% 1D, market cap $97.0M). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 18/20. Across 1016 tracked Health Care issuers, KEQU ranks #97 in composite RQD confidence.

How does KEQU compare to SERA and BNR in the Health Care sector?

Within the Health Care sector (Medical Specialities), KEQU carries a Roarable C+ (69/100 RQD), trailing P/E of 10.1x, gross margin of 28.5%, and ROIC of 16.7%. By comparison, SERA (Sera Prognostics Inc. (Class A)) holds a E grade (30/100 RQD, P/E N/A, ROIC -35.0%, cap $81.3M) and BNR (Burning Rock Biotech Limited) posts a E grade (20/100 RQD, P/E N/A, ROIC -35.0%, cap $116.5M). Among the 5-stock peer group, KEQU leads on earnings multiple (10.1x) while KEQU leads on capital efficiency (16.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KEQU?

Per KEQU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-04-30, CIK 0000055529), Kewaunee Scientific Corporation generated $282.0M in revenue (+17.3% YoY), $9.6M in net income, and $18.6M in free cash flow against $176.0M in total assets and $16.3M in total debt. Key quantitative strengths: Strong cash generator (29% profit margin)β€”profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KEQU trading relative to its 50-day, 200-day, and 52-week technical levels?

KEQU last traded at $33.44 (-0.21% on volume of 10,126 shares), positioning the stock -3.18% below its 50-day simple moving average ($34.54) and -9.13% below its 200-day simple moving average ($36.80). Across its 52-week range of $32.00 to $43.36, KEQU sits at the 12.7% percentile with a 14-day RSI of 49.8 (NEUTRAL RANGE) and an implied next-earnings move of Β±5.0% ($31.77 to $35.11).

KEQU Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

What is KEQU's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for KEQU.

Direct Sub-Reports: KEQU RQD Cockpit KEQU 12M Forecast KEQU Earnings & Move KEQU Dividends & DRIP KEQU Insiders & 13F KEQU Whale Options KEQU Profit Sankey KEQU News & Why
ROARABLE RATING BRIEF β€’ RQD 69/100 (C+) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

KEQU β€” Kewaunee Scientific Corporation: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:44:13Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, KEQU scores 69 out of 100 with a letter grade of C+ and a verdict of "Roarable Hold β€” Upper Neutral / Watch for Breakout." The five pillars are: Fundamental Cash Engine 17/20 (ROIC 16.7%; FCF yield 19.2%), Whale 13F Flow 6/20 (institutional accumulation and options positioning), Insider Conviction 18/20 (SEC Form 4 and Congressional PTR cluster flow), Macro Regime Fit 12/20 (Beta 1.0; sector sensitivity), and Forensic Balance Sheet 16/20 (Altman Z 3.37; Piotroski F 8/9; Debt/Equity 0.23). For a prospective investor, the strongest pillars are the cash engine and insider conviction, while the weakest is institutional flow at 6/20, indicating limited measured institutional accumulation in the source data. The balance sheet score supports the view that financial stress is not the primary concern. The verdict label signals a neutral posture with a watch for a directional breakout rather than a conviction call in either direction. The 19.2% FCF yield alongside a 10.1 trailing P/E illustrates a valuation tradeoff: cash generation appears high relative to market value, but the source data does not explain whether that yield is sustainable or what drove it.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
$33.51$97.0M10.18.56.33.320%1.0$32 - $43.3616.7%

Business

Kewaunee Scientific Corporation is a NASDAQ-listed issuer in the Health Care sector and Medical Specialities industry, per the profile section. The source data does not specify its products, customers, or revenue model beyond its reported financial results. Per the FY 2025 filing, revenue was $282.0M, indicating an operating scale in that range.

Financial Trend

PeriodRevenueOperating IncomeNet IncomeEPSFCFCashDebt
FY 2025$282.0M$16.7M$9.6MN/A$18.6M$8.2M$16.3M
FY 2024$240.5M$17.8M$11.4MN/A$14.8M$9.5M$35.0M
FY 2023$203.8M$18.3M$18.8MN/A$19.6MN/AN/A

Per the SEC financials, revenue grew from $203.8M in FY 2023 to $282.0M in FY 2025, while net income declined from $18.8M to $9.6M over the same span. Market data reports a gross margin of 28.5%, operating margin of 5.9%, and net margin of 3.4%, with ROIC of 16.7%. Per the Roarable RQD rating, the Altman Z-Score is 3.37 and the Piotroski F-Score is 8/9. Debt declined from $35.0M in FY 2024 to $16.3M in FY 2025, and the reported Debt/Equity ratio is 0.23.

Recent Catalysts & News Wire Analysis

Per the recent news and catalysts section, the dominant theme is a planned acquisition of lab dealer NYCOM. Investing.com reports Kewaunee to acquire NYCOM for $55M. A Stock Titan item states a $30M cash payment at closing forms part of the planned acquisition. A Stock Titan headline frames the deal as the U.S.'s largest lab dealer potentially joining Kewaunee. The remaining items are a TradingView estimates report, a Zacks analyst blog mention, and a Stock Traders Daily signal piece, each tagged with a yellow light and "MARKET WIRE" impact label. Risk watch items include the cash component of the acquisition relative to reported cash of $8.2M in FY 2025, and the source data does not state how the balance of consideration is funded. Proprietary signals in the Butterfly Supply-Chain Graph: none.

Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples

Per the Butterfly Supply-Chain Graph, the supply chain is NONE, with no butterfly links and no proprietary signals recorded. Upstream and downstream dependencies, sector correlations, and bottlenecks are not available in source data. The one ripple the source data does support is that a pending lab-dealer acquisition would connect Kewaunee to distribution activity, though the source data does not detail the mechanics of that connection.

Open Questions

  • How will the $55M NYCOM acquisition be financed, given FY 2025 cash of $8.2M and the stated $30M cash payment at closing?
  • What drove net income to fall from $18.8M in FY 2023 to $9.6M in FY 2025 while revenue rose?
  • What are the company's EPS figures, which are reported as N/A in every period?
  • What institutional and insider holders are behind the insider conviction score, given no holders data is provided?
  • What products and customers generate the reported revenue?

KEQU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Kewaunee Scientific Corporation (KEQU) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to KEQU Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

KEQU Bull vs. Bear Conversation Board β€” What's Your Call at $33.44?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON KEQU 🐻 50% BEARISH CONVICTION
1. Pick Your Side on KEQU:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $36.19 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is KEQU (C+ β€’ RQD 69/100) a Buy at $33.51?

Welcome to the KEQU (Kewaunee Scientific Corporation) Roar Pit. Current RQD Composite is 69/100 (Roarable Hold β€” Upper Neutral / Watch for Breakout) in Medical Specialities. Bulls point to capital efficiency (16.7% ROIC), while bears focus on macro rate sensitivity and margin execution. Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

VA ValDiscipline Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $25.47 (-24.0%)
Spot @ $33.51

Pump the brakes on KEQU β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on KEQU, but look at what you are paying: 10.1x trailing P/E with 28.5% gross margins. Unless Kewaunee Scientific Corporation expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

SI SiliconVal_Bull Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $39.21 (+17.0%)
Spot @ $33.51

KEQU cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on KEQU, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $33.51 (52-wk range $32.00 - $43.36), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%